WO2003048204A1 - Alzheimer’s disease-associated gene and protein and use thereof - Google Patents
Alzheimer’s disease-associated gene and protein and use thereof Download PDFInfo
- Publication number
- WO2003048204A1 WO2003048204A1 PCT/JP2002/012749 JP0212749W WO03048204A1 WO 2003048204 A1 WO2003048204 A1 WO 2003048204A1 JP 0212749 W JP0212749 W JP 0212749W WO 03048204 A1 WO03048204 A1 WO 03048204A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- disease
- alzheimer
- associated gene
- gene
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002354433A AU2002354433A1 (en) | 2001-12-06 | 2002-12-05 | Alzheimer's disease-associated gene and protein and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001373050 | 2001-12-06 | ||
JP2001-373050 | 2001-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003048204A1 true WO2003048204A1 (en) | 2003-06-12 |
Family
ID=19181834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/012749 WO2003048204A1 (en) | 2001-12-06 | 2002-12-05 | Alzheimer’s disease-associated gene and protein and use thereof |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002354433A1 (ja) |
WO (1) | WO2003048204A1 (ja) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058356A1 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 50 human secreted proteins |
-
2002
- 2002-12-05 AU AU2002354433A patent/AU2002354433A1/en not_active Abandoned
- 2002-12-05 WO PCT/JP2002/012749 patent/WO2003048204A1/ja active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000058356A1 (en) * | 1999-03-26 | 2000-10-05 | Human Genome Sciences, Inc. | 50 human secreted proteins |
Non-Patent Citations (7)
Title |
---|
DATABASE BIOSIS [online] KOMANO H. ET AL.: "A new functional screening system identified cDNA which increase gamma-cleavage", XP002965865, accession no. DIALOG Database accession no. 200100482637 * |
DATABASE BIOSIS [online] SAI X. ET AL.: "ER stress- induced membrane-associated protein increases gamma-cleavage", XP002965866, accession no. DIALOG Database accession no. 200100552012 * |
KOMANO H. ET AL.: "A new functional screening system for identification of regulators for the generation of amyloid beta-protein", J. BIOL. CHEM., vol. 277, no. 42, October 2002 (2002-10-01), pages 39627 - 39633, XP002965868 * |
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 1439 * |
SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 1, November 2001 (2001-11-01), pages 512 * |
SUDOH S. ET AL.: "Intracellular site of gamma-secretase cleavage for Abeta42 generation in neuro 2a cells harbouring a presenilin 1 mutation", EUR. J. BIOCHEM., vol. 267, no. 7, April 2000 (2000-04-01), pages 2036 - 2045, XP002951097 * |
TOUCHOT N. ET AL.: "Biochemical properties of the YPT-related rab1B protein comparison with rab1A", FEBS LETT., vol. 256, no. 1-2, 1989, pages 79 - 84, XP002965867 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104580A1 (en) | 2007-03-01 | 2008-09-04 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
EP2481408A2 (en) | 2007-03-01 | 2012-08-01 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
EP2865670A1 (en) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
WO2011029920A1 (en) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
WO2011110613A1 (en) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
EP3461819A1 (en) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
Also Published As
Publication number | Publication date |
---|---|
AU2002354433A1 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003014162A1 (en) | ANTIBODY RECOGNIZING GM1 GANGLIOSIDE-BOUND AMYLOID β-PROTEIN AND DNA ENCODING THE ANTIBODY | |
WO2006014638A3 (en) | ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS | |
EP2082747A3 (en) | Treatment for Alzeimer's disease | |
WO2004074232A8 (en) | 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases | |
EP2465872A3 (en) | Anti-ADDL antibodies and uses thereof | |
WO2004064806A3 (en) | Process for modifying drug crystal formation | |
WO2007059341A3 (en) | Pyrazolothiazole protein kinase modulators | |
WO2003028631A3 (en) | Drug targets for alzheimer's disease and other diseases associated with decreased neuronal metabolism | |
WO2003001983A3 (en) | Methods for diagnosing and treating a disease mediated by decreased mmp-2 function | |
AU2002330215A1 (en) | Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease | |
WO2003048204A1 (en) | Alzheimer’s disease-associated gene and protein and use thereof | |
WO2006078853A3 (en) | Thioredoxin interacting protein (txnip) as regulator of vascular function | |
WO2005003103A3 (en) | 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases | |
DE102005055128A1 (de) | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor | |
WO2007067512A3 (en) | Method for identifying modulators of adprh useful for treating alzheimer's disease | |
WO2006091964A8 (en) | Regulators of protein misfolding and aggregation and methods of using the same | |
CA2534643A1 (en) | Methods for screening and identifying compounds | |
AU2003273310A1 (en) | Substituted aminoethers for the treatment of alzheimer's disease | |
WO2003012141A1 (en) | Method of screening alzheimer’s disease-associated gene | |
AU2001232275A1 (en) | Novel collagen-like protein clac, precursor thereof and genes encoding the same | |
WO2004005540A3 (de) | Verwendungen von an ngal bindenden substanzen zur diagnose und behandlung von krebserkrankungen | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
WO2005002573A3 (en) | Methods for using modulators of proline-rich tyrosine kinase 2 | |
WO2007048034A3 (en) | Use of androgens for the treatment of parkinson' s disease | |
WO2006105038A3 (en) | Methods of altering gene expression and methods of treatment utilizing same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |